Kyle Jenne
Net worth: 2 M $ as of 2026-05-30
Net worth: 2 M $ as of 2026-05-30
Kyle Jenne currently works at Ionis Pharmaceuticals, Inc., as Chief Global Product Strategy Officer & EVP from 2024.
Mr. Jenne also formerly worked at Elsie Biotechnologies Inc., as Chief Executive Officer & Director, Ionis Pharmaceuticals, Inc., as Chief Commercial Officer & Executive VP, and Akcea Therapeutics, Inc., as Senior Vice President-US Commercial from 2017 to 2019.
Mr. Jenne received his undergraduate degree from Arizona State University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-15 | 23,713 ( 0.01% ) | 2 M $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2024-02-28 |
| Companies | Position | End |
|---|---|---|
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Elsie Biotechnologies Inc.
Elsie Biotechnologies Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops oligonucleotide therapeutics | Chief Executive Officer | - |
| AKCEA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops antisense drugs | Health Technology |
Arizona State University
Arizona State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for cardiometabolic lipid disorders | Health Technology |
Elsie Biotechnologies Inc.
Elsie Biotechnologies Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops oligonucleotide therapeutics | Health Technology |
Select your edition
All financial news and data tailored to specific country editions